https://www.zacks.com/stock/news/2204413/arcadis-nv-arcay-is-a-great-choice-for-trend-investors-here-s-why?cid=CS-ZC-FT-tale_of_the_tape|recent_price_strength_screen-2204413
Jan 02, 2024 - If you are looking for stocks that are well positioned to maintain their recent uptrend, Arcadis NV (ARCAY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
zc:-2171278960479727824
0
https://www.zacks.com/stock/news/2206412/nvs-or-lly-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2206412
Jan 05, 2024 - NVS vs. LLY: Which Stock Is the Better Value Option?
zc:-3007458117815957684
0
https://www.zacks.com/commentary/2211005/these-stocks-are-showing-relative-strength-as-s-p-500-stalls-near-record-high?cid=CS-ZC-FT-investment_ideas-2211005
Jan 16, 2024 - As investors, our job isn't to predict an unknowable future.
zc:7680586662624644437
0
https://www.zacks.com/stock/news/2220214/pharma-stock-roundup-pfe-mrk-nvo-sny-s-q4-earnings-fda-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-2220214
Feb 02, 2024 - Pfizer (PFE), Merck (MRK), Novartis (NVS), Novo Nordisk (NVO) and Sanofi (SNY) announce fourth-quarter and full-year 2023 results.
zc:4214353983792327271
0
https://www.zacks.com/stock/news/2223529/biotech-stock-roundup-gild-amgn-bmy-s-q4-results-mor-up-on-nvs-deal-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2223529
Feb 08, 2024 - Earnings of Gilead (GILD) and Amgen (AMGN) are in focus in the biotech sector.
zc:3389672683287065650
0
https://www.zacks.com/stock/news/2225414/gilead-gild-to-buy-cbay-for-4-3b-add-pbc-drug-to-pipeline?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2225414
Feb 13, 2024 - Gilead (GILD) is all set to acquire CymaBay Therapeutics for $4.3 billion and strengthen its liver disease portfolio with the addition of seladelpar to its pipeline.
zc:-2849976509115006595
0
https://www.zacks.com/stock/news/2227293/ionis-ions-olezarsen-gets-fda-s-orphan-tag-for-rare-disease?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2227293
Feb 16, 2024 - FDA grants orphan drug status to Ionis' (IONS) olezarsen for treating familial chylomicronemia syndrome (FCS). An NDA for olezarsen is expected to be filed this year.
zc:-4389715286765519151
0
https://www.zacks.com/stock/news/2228151/roche-s-rhhby-xolair-gets-approval-for-food-allergies?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2228151
Feb 19, 2024 - Roche (RHHBY) obtains FDA approval for Xolair for the treatment of children and adults with one or more food allergies.
zc:2421545480960216920
0
https://www.zacks.com/stock/news/2238200/what-makes-mainz-biomed-nv-mynz-a-new-buy-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2238200
Mar 08, 2024 - Mainz Biomed NV (MYNZ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
zc:2752182196277331989
0
https://www.zacks.com/stock/news/2238956/novartis-nvs-advances-while-market-declines-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2238956
Mar 11, 2024 - Novartis (NVS) closed the most recent trading day at $101.37, moving +0.66% from the previous trading session.
zc:-8340105195982078511
0